Preventative treatment of chronic migraine will continue to evolve in short-term with anti-CGRP mAbs effectiveness Read more
Takeda’s phase 2b study of Mezagitamab shows potential to transform treatment of primary immune Thrombocytopenia Read more
CALQUENCE plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial Read more
China’s Innovent holds potential to change pancreatic cancer treatment with bispecific antibody IBI389: GlobalData Read more